Tonbo Imaging has raised ₹413 crore from institutional investors like SBI Mutual Fund and HDFC Life, valuing the defence electronics firm at ₹4,000 crore. This secondary share sale precedes the company's ₹852 crore IPO, scheduled to open on October 15, 2026. Because the IPO is entirely an Offer for Sale, the company will not receive new funds from the issue.
Tonbo Imaging India Ltd has completed a significant secondary share sale, raising ₹413 crore from a group of institutional investors just days before its public market debut. Participants in this round included SBI Mutual Fund, HDFC Life Insurance, and Amansa Investments. These transactions, which took place in late September 2026, valued the company at approximately ₹4,000 crore and were executed at ₹700 per share. This price point aligns with the upper end of the price band for the company's upcoming Initial Public Offering (IPO).
The IPO is set to open for subscription on October 15 and will close on October 19, 2026. The issue is entirely an Offer for Sale (OFS), meaning that existing shareholders and promoters will be selling their stakes, and the company will not receive any fresh capital from the public offering to fund its operations or expansion. The offering is valued at ₹852.18 crore, with a price band set between ₹665 and ₹700 per share. Shares are tentatively scheduled to list on the BSE and NSE on October 23, 2026.
Tonbo Imaging operates as an original equipment manufacturer in the defence electronics space, specializing in advanced electro-optical and imaging systems. Its product portfolio includes thermal imaging, weapon sights, and missile guidance technologies, which have been deployed in over 24 countries. The company has positioned itself as a critical supplier for defence forces and homeland security agencies, leveraging proprietary technology to compete in the global defence supply chain.
For investors evaluating the business, it is important to understand the specific nature of its operational model and potential risks. The company’s revenue growth is heavily dependent on long and often unpredictable government tender cycles. Because defence procurement can be slow and subject to budget constraints, the company’s order book may experience volatility. Additionally, the business model relies on third-party contract manufacturers for production, which creates an outsourcing dependency. The company also faces supply chain risks related to the procurement of critical raw materials, such as Germanium, which are essential for its high-tech imaging products.
While the institutional backing indicates confidence in the company’s technological niche, the reliance on non-recurring, tender-based contracts remains a key factor to watch. As the IPO process moves forward, investors will be monitoring the subscription trends for the OFS and the company’s ability to manage its supply chain and contract execution effectively post-listing.